Compare KBSX & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KBSX | CRDF |
|---|---|---|
| Founded | 1976 | 1999 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 67.1M |
| IPO Year | 2024 | 2012 |
| Metric | KBSX | CRDF |
|---|---|---|
| Price | $1.31 | $0.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | $3.50 | ★ $6.28 |
| AVG Volume (30 Days) | 5.2K | ★ 364.0K |
| Earning Date | 10-29-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $365,993.00 |
| Revenue This Year | $18.93 | N/A |
| Revenue Next Year | $13.80 | $11.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $0.81 | $0.72 |
| 52 Week High | $1.79 | $3.31 |
| Indicator | KBSX | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 47.06 | 30.76 |
| Support Level | $1.09 | N/A |
| Resistance Level | $1.41 | $1.13 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 51.35 | 5.60 |
FST Corp is a renowned manufacturer and innovator in the golf industry with a growing portfolio of creative golf products, including acclaimed golf club shafts and other equipment. The Company has engaged in the research, development, manufacturing, and sales of golf club shafts. The Company currently produces and sells golf club shafts under the Company's own high performance KBS golf club shaft brand, and serves as an original equipment manufacturer (OEM) and original design manufacturer (ODM) for other world-renowned golf equipment brands, golf equipment OEMs, and golf equipment distributors that provide consumers with customized golf club services.
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.